Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Response Genetics Inc
RGDXQResponse Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. Address: 1640 Marengo Street, Los Angeles, CA, United States, 90033
Analytics
Preço Alvo de Wall Street
1.8 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave RGDXQ
Análise de Dividendos RGDXQ
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos RGDXQ
Avaliação de ações RGDXQ
Relatório RGDXQ
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |